Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in tumour response compared with chemotherapy (moderate certainty).
Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
The review found no eligible studies for this question.
Anti‐CTLA4 monoclonal antibodies with leads to lower progression‐free survival† compared with without anti‐PD1 monoclonal antibodies (high certainty).
Anti‐CTLA4 monoclonal antibodies with leads to higher tumour response compared with without anti‐PD1 monoclonal antibodies (high certainty).
Anti‐CTLA4 monoclonal antibodies with showed no clear difference in toxicity (≥ G3) compared with without anti‐PD1 monoclonal antibodies (low certainty).
BRAF inhibitors leads to lower overall survival† compared with chemotherapy (high certainty).
BRAF inhibitors leads to lower progression‐free survival† compared with chemotherapy (high certainty).
BRAF inhibitors leads to higher tumour response compared with chemotherapy (high certainty).
Anti‐PD1 monoclonal antibodies probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
BRAF inhibitors showed no clear difference in toxicity (≥ G3) compared with chemotherapy (low certainty).
MEK inhibitors showed no clear difference in overall survival† compared with chemotherapy (low certainty).
MEK inhibitors probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
MEK inhibitors leads to higher tumour response compared with chemotherapy (high certainty).
MEK inhibitors probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
BRAF plus MEK inhibitors leads to lower overall survival† compared with BRAF inhibitors (high certainty).
BRAF plus MEK inhibitors probably leads to lower progression‐free survival† compared with BRAF inhibitors (moderate certainty).
BRAF plus MEK inhibitors leads to higher tumour response compared with BRAF inhibitors (high certainty).
BRAF plus MEK inhibitors showed no clear difference in toxicity (≥ G3) compared with BRAF inhibitors (moderate certainty).
Anti‐angiogenic drugs plus chemotherapy probably leads to lower overall survival† compared with chemotherapy (moderate certainty).